Nanobac Pharmaceuticals, Incorporated
NNBP
$0.00
$0.000.00%
OTC PK
| 12/31/2007 | 09/30/2007 | 06/30/2007 | 03/31/2007 | 12/31/2006 | |
|---|---|---|---|---|---|
| Revenue | -92.18% | -96.39% | -93.73% | -89.67% | -65.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -92.18% | -96.39% | -93.73% | -89.67% | -65.73% |
| Cost of Revenue | -81.70% | -92.71% | -90.67% | -83.15% | -65.23% |
| Gross Profit | -97.87% | -98.52% | -95.45% | -93.13% | -66.02% |
| SG&A Expenses | 121.09% | 125.67% | 133.44% | 140.75% | 0.20% |
| Depreciation & Amortization | -14.96% | -24.76% | -32.11% | -38.19% | -28.78% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.30% | 45.72% | 51.09% | 59.34% | 11.45% |
| Operating Income | -20.83% | -65.29% | -76.70% | -94.58% | -29.32% |
| Income Before Tax | -49.01% | -68.90% | -72.59% | -84.85% | -19.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -49.01% | -68.90% | -72.59% | -84.85% | -19.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.01% | -68.90% | -72.59% | -84.85% | -19.69% |
| EBIT | -20.83% | -65.29% | -76.70% | -94.58% | -29.32% |
| EBITDA | -27.02% | -87.52% | -108.71% | -143.64% | -50.56% |
| EPS Basic | -23.87% | -43.35% | -48.00% | -60.94% | -14.43% |
| Normalized Basic EPS | 0.00% | -41.18% | -47.00% | -63.16% | 1.67% |
| EPS Diluted | -23.87% | -43.35% | -48.00% | -60.94% | -14.43% |
| Normalized Diluted EPS | 0.00% | -41.18% | -47.00% | -63.16% | 1.67% |
| Average Basic Shares Outstanding | 22.69% | 18.42% | 14.74% | 9.65% | 4.56% |
| Average Diluted Shares Outstanding | 22.69% | 18.42% | 14.74% | 9.65% | 4.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |